New Bone-Boosting shot tested for first time in humans

NCT ID NCT07178327

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tests a new injectable drug called LYN101 in 44 people. First, healthy volunteers get a single dose to check safety. Then, postmenopausal women with low bone mass get multiple doses to see how the drug affects bone turnover markers. The main goal is safety, not yet proof that it prevents fractures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LYN101 (injectable drug)

What this could lead to

If successful, this could point toward a new treatment to strengthen bones and reduce fracture risk in osteoporosis.

What could go wrong

This is a very early Phase 1 trial with only 44 participants, focused on safety. It is too small and early to know if LYN101 will actually help bones or be safe long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Osteoporotic Fractures postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Sixth People's Hospital

    Shanghai, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, 233060, China